Anteris Technologies Global Corp. · NASDAQ:AVR

Anteris Technologies Global — Shareholder Meeting (May 2022)

81 slides from Anteris Technologies Global's shareholder meeting presentation, May 25, 2022

  1. Slide 1: Anteris 2021 AGM CEO Presentation

    ANTERIS 2021 AGM CEO PRESENTATION May 25th 2022 www.anteristech.com | Follow us @anteristech Copyright Anteris Technologies Ltd 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains general information which is current as at 25 May 2022. It is information given in summary form and does not purport to be complete. Information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not tak

  3. Slide 3: 2016 to 2019

    2016 a~ 2019

  4. Slide 4: Agenda

    Agenda • Financials • Competitive advantage • First in Human study • Market opportunity • Partnerships • Future revenues • Questions

  5. Slide 5: 2021 A year of headlines

    2021 A year of headlines

  6. Slide 6: Ba oor .ce devoted to his queen, dead at

    Ba oor .ce devoted to his queen, dead at 99

  7. Slide 7: PUNTER'S WHO'S OFF

    PUNTER'S WHO'S OFF LAST STAND THE LIST DETAILS > SPORT 5 ERFUL >Pi8, 19 FROG STRUCK DOWN BY LIGHTNING .. and a few hum ly hit too >>P2 TERRITORY SCHOOL ARDS) PAGE 3 a

  8. Slide 8: Slide 8

  9. Slide 9: Anteris made a few of its own headlines

    Anteris made a few of its own headlines

  10. Slide 10: Major milestones were achieved in 2021

    Major milestones were achieved in 2021 AUGUST OCTOBER Close $8.82 Close $8.50 APRIL Extended Manufacturing Key Animal Study for EFS Close $9.85 Agreement (LeMaitre) Submission Completed FEBRUARY JUNE Close $7.11 ComASUR™ Key Milestone Key Partnerships with Close $6.80 IQVIA & CRF and Piper DECEMBER

  11. Slide 11: DurAVR studies progressed rapidly in 2021 from animals to humans

    DurAVR™ studies progressed rapidly in 2021 from animals to humans Animal lab Dr Hamid performing echo Dr Meduri implanting DurAVR™ being deployed DurAVR™

  12. Slide 12: 2021 Financials

    Equity statement ¢ ent 7 1,774,576

  13. Slide 13: Financial highlights 2021

    Financial highlights 2021 13

  14. Slide 14: Anteris market cap increased by 515% in 2021

    Anteris market cap increased by 515% in 2021 Key financial metrics FY2020 FY2021 • 10% increase in ADAPT® sales Actual Actual $m $m • Overall increase in expenses primarily reflects increased research and development Sales revenue 7.1 7.8 expenditure relating to the Group’s Transcatheter Aortic Valv

  15. Slide 15: Focused investment in R&D has accelerated progress

    Focused investment in R&D has accelerated progress Research & Development $19.5M Corporate & Operational $3.4M • DurAVRTM valve development program • Capital raising costs • Tblisi first-in-human trials • Company compliance costs • Design of the TAVR delivery system • Insurance • Regulatory and Medi

  16. Slide 16: Operational costs remain stable 20/21

    Operational costs remain stable 20/21 $25.0 M $22.9 M $20.0 M $19.5 M • Corporate + operational costs stable from 2020 to 2021 $15.3 M $15.0 M • R&D costs increased as we $12.2 M entered human studies $10.0 M $5.0 M $0.0 M 2020 2021 Project (TAVR) result Group result 16

  17. Slide 17: Increasing CardioCel production with decreasing costs

    Increasing CardioCel™ production with decreasing costs 2020: 20,589 units • 77% increase in units • 23% increase in costs 15,644 units 2021: • 32% increase in units • 2% decline in costs 8,850 units 2019 2020 2021 Total costs ($) Units 17

  18. Slide 18: Highly productive workforce

    Highly productive workforce TOTAL EMPLOYEE NUMBERS DIVERSITY 2021 FEMALE MALE 2020 2019 47% 46% 47% 53% 54% 53% 91 42 44 51 FY 16 Dec 19 Dec 20 Dec 21 18

  19. Slide 19: Increased cash balance from equity and non dilutive sources

    Increased cash balance from equity and non dilutive sources $40.0 M Perceptive investment $30.0 M LeMaitre sale of distribution rights $20.0 M Exercise of Rights unlisted options issue $10.0 M $0.0 M Mar-18 Sep-18 Mar-19 Sep-19 Mar-20 Sep-20 Mar-21 Sep-21 Mar-22 Cash (including term deposits) Operat

  20. Slide 20: Increasing share price and company valuation

    Increasing share price and company valuation $250 M $17.00 $18.00 $15.96 $16.00 $12.96 $230.8 M $200 M $217.4 M $14.00 $12.00 $150 M $10.00 $10.00 $143.8 M $6.80 $8.00 $100 M $6.20 $6.00 $4.90 $6.00 $3.75 $4.00 $50 M $59.1 M $47.2 M $36.6 M $2.00 $35.4 M $29.0 M $23.4 M $0 M $0.00 Dec 2018 Jun 2019

  21. Slide 21: AVR has returned 141% since the CardioCel divestiture

    AVR has returned 141% since the CardioCel™ divestiture • The S&P/ASX Emerging Companies Index (XEC) is a benchmark consisting of 200 Australian microcap AVR return XEC return companies ranked anywhere between 350 to 600 by market capitalisation Rolling 12 months 84% 17% • The below graph compares th

  22. Slide 22: AVR has out performed all major health care indices

    AVR has out performed all major health care indices 160% Rolling 12 months 140% AVR May 2022 120% S&P/ASX Emerging Companies 100% 80% Stoxx Europe 600 Health Care 60% S&P Composite 1500 Health Care 40% 20% Dow Jones US Medical Equipment Index 0% NASDAQ Health -20% Care Index -40%

  23. Slide 23: AVR outperformed major competitors

    AVR outperformed major competitors Share price movement (8 April – 9 May 2022) 10% Anteris 5% Boston Scientific 0% -5% -10% Medtronic -15% Edwards Lifesciences -20% -25%

  24. Slide 24: Top 40 investors hold 61% of the Company

    Top 40 investors hold 61% of the Company OWNERSHIP COUNTRY SHAREHOLDER MIX AUSTRALIA 68% L1 CAPITAL SIO CAPITAL 8% 9% OTHER 1% OTHER TOP 40 NEW 30% ZEALAND UNITED PERCEPTIVE 4% STATES LIFE 27% SCIENCES 14% 70% INVESTOR TYPE HISTORY 60% 50% March 2021 40% 30% May 2022 20% OTHER SHAREHOLDERS 10% 39% 0

  25. Slide 25: Financials only tell part of the story

    Financials only tell part of the story

  26. Slide 26: How do we compare?

    How do we compare ?

  27. Slide 27: What is our competitive advantage?

    What is our competitive advantage ?

  28. Slide 28: ADAPT + DurAVR + ComASUR

    ADAPT® + DurAVR™ + ComASUR™ For lifetime management of Aortic Stenosis patients www.anteristech.com | Follow us @anteristech Copyright Anteris Technologies Ltd 2021

  29. Slide 29: Slide 29

  30. Slide 30: ADAPT the best anti calcification treatment in the world

    ADAPT® the best anti calcification treatment in the world 1. Data on file, Admedus 2. Data on File, Admedus; AGRF DNA Extraction Reports (CAGRF16022 and CAGRF 15684), 2017 3. Neethling et al. Enhanced biostability and biocompatibility of decellularized bovine pericardium, crosslinked with an ultra-l

  31. Slide 31: Slide 31

  32. Slide 32: Aortic stenosis is a disease of calcification

    Aortic stenosis is a disease of calcification Calcium deposits cause a narrowing of the valve opening and an increase in pressure Calcium build up in valve with stenosis

  33. Slide 33: DurAVR: first and only 3D single piece TAVR valve

    DurAVR™ – the first and only 3D single piece TAVR valve in the world • Designed to be anatomically correct Lasts Longer • Restores pre disease haemodynamics Works Better • Has greater structural integrity • Opens wider (80%)

  34. Slide 34: Slide 34

  35. Slide 35: Younger patients need new solutions that Last Longer and Work Better

    Younger patients need new solutions that Last Longer and Works Better Younger patients need longer lasting next generation valve technology Younger Patient Age Key Considerations patients now eligible Valves now What Does Life Guidelines need to last Expectancy TAVR as class(I) for ages 65-80 this M

  36. Slide 36: ComASUR Delivery System

    ComASUR™ Delivery System a ANTERIS

  37. Slide 37: Slide 37

  38. Slide 38: Severe aortic stenosis requires the aortic valve to be replaced

    Severe aortic stenosis requires the aortic valve to be replaced SAVR (Surgical Aortic Valve TAVR (Transcatheter Aortic Replacement) Valve Replacement)

  39. Slide 39: Today's TAVRs need to address key medical needs

    Current TAVR devices Todays TAVR’s need to address 4 key medical needs Current products fall short in two critical areas Predictable Optimal Low Incidence of Procedure Hemodynamic Durability Complications Performance Competitor products can start Competitor products leave the to deteriorate within 1

  40. Slide 40: DurAVR THV satisfies all key areas

    Current TAVR devices DurAVR™ THV satisfies all 4 key areas ComASUR™ delivery system is Better haemodynamics at rest DurAVR’s™ 3D uni-body design has greater more predictable with and during increased cardiac structural integrity + ADAPT® anti commissural alignment output (exercise) calcification tre

  41. Slide 41: Slide 41

  42. Slide 42: Current TAVR products were not designed for younger patients

    Current TAVR products were not designed for younger patients 1st Generation TAVR’s designed to solve a different problem to today’s patients needs “Patient needs a valve that restores an active Patient needs a safe alternative to lifestyle for the rest of their life” open heart surgery” 1st and 2nd

  43. Slide 43: Skate to where the puck is going

    "Skate to where the puck is going not where it has been." — Wayne Gretzky

  44. Slide 44: Before the breakthrough comes the trial

    HUMAN BEFORE THE BREAKTHROUGH COMES THE TRIAL

  45. Slide 45: Slide 45

  46. Slide 46: DurAVR First-in-Human Study: Individual Patient Case Example

    DurAVR™ First-in-Human Study: Individual Patient Case Example FIH 30-day DurAVR™ haemodynamics: • Area Derived Annulus Size 21.3mm • EOA = 2.02 cm2 • DVI = 0.66 • Intra-op Coaptation length = 10.3 mm EOA compared to annulus size matched benchmark*: • Sapien 3 = 1.41 cm2 +/- 0.27 • Evolut R = 1.66 cm

  47. Slide 47: ComASUR: A unique physician designed delivery system

    ComASUR™ A unique Physician designed delivery system Easy and Predictable Commissural Alignment • Intuitive handle design • Precise balloon expandable deployment • Unique ability to rotate valve at annular level for consistent, predictable commissural alignment

  48. Slide 48: Near perfect laminar flow, unique in the valve space

    Near perfect laminar flow, unique in the valve space Poor laminar flow observed in other products leads to early valve deterioration. == == DurAVR™ has perfect laminar flow!

  49. Slide 49: We were successful in the most challenging patient group

    We were successful in the most challenging patient group Severe Annular Calcium Extreme Leaflet Calcium Type 1 Bicuspid

  50. Slide 50: DurAVR First-in-Human Study Challenging Anatomical Conditions Treated

    DurAVR™ First-in-Human Study Challenging Anatomical Conditions Treated Severe Annular Extreme Leaflet Calcium Calcium Type 1 Bicuspid Baseline CTs

  51. Slide 51: DurAVR - Commissural alignment

    DurAVR™ - Commissural alignment Excellent Commissural Alignment & Leaflet Function 30-day CT

  52. Slide 52: DurAVR different to the competitors by design

    DurAVR™ Different to the competitors by design Unique Design of a Single Piece of Tissue 3D Molded to Mimic the Native Aortic Valve Anatomy • Designed in diastole (closed position) • Opens wider with less pressure • Remains open longer with the purpose of CURRENT VALVES improving haemodynamics * Dat

  53. Slide 53: DurAVR THV: Outperforms the competitors in every regard

    DurAVR™ THV: Outperforms the competitors in every regard DurAVR™ Computational Fluid Model* Diastole Systole Coaptation Modeling* • 85% greater coaptation area** • 35% lower leaflet strain** • Optimal laminar flow* *Data on file, Anteris **Lim KH et al., Flat or Curved Pericardial Aortic Valve Cusps

  54. Slide 54: DurAVR 3D Single Piece THV with ADAPT

    DurAVR™ 3D Single Piece THV with ADAPT® Exercise Capacity Durability Future Management Valve that restores near-normal haemodynamics Valve that lasts the lifetime of the patient Valve that allows for future intervention PROVEN TISSUE DURABILTY Superior anti-calcification tissue process (ADAPT®)* IMP

  55. Slide 55: id people

    id people y wanted, nave said er horse - Henry Ford

  56. Slide 56: In the end its all about patients

    In the end its all about patients

  57. Slide 57: Next cohort of patients being implanted now

    Next cohort of patients being implanted now !

  58. Slide 58: Tbilisi, Georgia first-in-human

    ANTERIS TECHNOLOGIES A Structural Heart Company TBILISI, GEORGIA, 25/5/22. FIH.

  59. Slide 59: Market opportunity

    Market opportunity

  60. Slide 60: AVR Market Growth

    AVR Market Growth • USD 14 billion by 2028 • US CAGR 12% • US 42% of the market in 2021 • 75% of AVR will be TAVR by 2028

  61. Slide 61: The Global TAVR market will continue to show strong growth

    The Global TAVR market will continue to show strong growth into the future TAVR PROCEDURES 2020 -2028 TAVR REVENUE 2020 -2028 US OUS US OUS CAGR US 11.4% CAGR OUS 9% USD Billions 242 229 $9 215 $9 202 $8 190 $8 174 $7 $7 154 $6 134 $5 118 $4 165.73 174.78 145.9147 155.7 $5 122.4052 136.0115 $4 $5 $5

  62. Slide 62: TAVR/SAVR Regional Market share

    TAVR/SAVR Regional Market share 2021 TAVR/Surgical Aortic TAVR Procedures by Stenosis Procedures EU TAVR Market Share 2021 Regions 2% 6% 225445, 42% 4% 10% 9% Edwards 43% Medtronic Edwards Boston Abbott Others 45% 39% Medtronic TAVR EU 305580, 58% Surgery US US TAVR Market Share 2021 5% 42% Medtroni

  63. Slide 63: 2021 TAVR Market Share US EU

    2021 TAVR Market Share US EU US Market TAVR Share 2021 EU TAVR Market Share 2021 5% 2% 6% 10% 31% 43% 64% 39% Edwards Medtronic Boston Abbott Others Edwards Medtronic Abbott

  64. Slide 64: 2021 to 2028 TAVR vs Surgical Procedures: US

    2021 to 2028 TAVR vs Surgical Procedures: US 2028 US TAVR/Surgical Aortic Stenosis Procedures 2021 US TAVR/Surgical Aortic Stenosis Procedures 56404, 24% 81079, 47% 90960, 53% 174780, 76% TAVR Total Surgical (no TAVR) TAVR Total Surgical (no TAVR)

  65. Slide 65: 2021 Global Procedures vs Revenue

    2021 Global Procedures vs Revenue Global 2021 TAVR Surgical Aortic Stenosis Procedures Global 2021 TAVR Surgical Revenue US$ 1,124,450,988.13 , 18% 225445, 42% 305580, 58% 5,241,724,662.90 , 82% TAVR Total Surgical (no TAVR) TAVR Total (excl TAVR)

  66. Slide 66: Key Partnerships

    Key Partnerships • Anteris has entered key Academic partnerships with the following: • Yale University • Columbia University • UWA

  67. Slide 67: Partnerships for next generation valve materials

    We are also engaged in partnerships for next generation valve materials • Currently Anteris is actively researching two distinct technologies that will allow us to replicate the design benefits of the DurAVR™ valve in new materials The company has entered multiple partnerships researching alternate

  68. Slide 68: Future Revenues

    | Future Revenues

  69. Slide 69: First TAVR revenues in 2023

    First TAVR revenues in 2023 • Anteris TAVR studies will potentially qualify as a Category B study • Anteris will commence supplying product during its FDA studies at approx USD25k per unit • First TAVR revenues will commence in 2023

  70. Slide 70: Key presentations

    | * Key presentations

  71. Slide 71: DurAVR will be featured at key medical conferences in 2022

    DurAVR™ will be featured at key medical conferences in 2022 Q1 Q2 Q3 Q4 Feb 26-Mar 1 May 17-20 June 8-11 Sep 16-20 Nov 27-29 Washington DC Pairs Chicago Boston London 2022 JAN Feb MAR APR MAY JUN JUL AUG SEP OCT NOV DEC Podium: Podium: Podium: Podium: Podium: Innovation PCR Innovation Submitted: New

  72. Slide 72: Slide 72

  73. Slide 73: Questions

    Questions • Market valuation • When can we start selling DurAVR™ • Nasdaq listing progress/structure • Development milestones • FIH TAVR • SAVR study • EFS FDA study • R&D Further developments

  74. Slide 74: Slide 74

  75. Slide 75: Slide 75

  76. Slide 76: Board of Directors

    Board of Directors John Seaberg Wayne Paterson Stephen Denaro Wenyi Gu Director and Chair Director and Director and Director Chief Executive Officer Company Secretary 76

  77. Slide 77: Executive Team

    Executive Team David St. Denis Matthew McDonnell Christopher Meduri Chief Operating Officer Chief Financial Officer Chief Medical Officer 77

  78. Slide 78: Anteris is supported by highly qualified advisors

    Anteris is supported by highly qualified advisors Bernard Prendergast, MD Samir Kapadia, MD Gorav Ailawadi, MD Guy’s & St. Thomas’ Michael Reardon, MD Karl Poon, MBBS Jayme Bennetts, BMBS Cleveland Clinic Univ of Virginia Charlottesville, VA Nicolas Van Mieghem, MD London, UK (A/S) Houston Methodist

  79. Slide 79: Anteris has a highly talented and engaged team

    Anteris has a highly talented and engaged team

  80. Slide 80: A great team in the right locations

    A great team in the right locations Exceptional individuals doing exceptional things USA Europe APAC Innovation Centre & Corporate HQ (Minneapolis, USA) Biologics Manufacturing / R&D Strategic Hub in Europe (Malaga, Australia) (Geneva, Switzerland) Finance & IT Team (Brisbane, Australia) Confidentia

  81. Slide 81: Lasts Longer, Works Better

    ANTERIS CHNOLOGIES A Structural Heart Lasts Longer, Works Better A Valve Designed for Life. DurAVR’ TRANSCATHETER HEART VALVE SYSTEM

Anteris Technologies — Shareholder Meeting (May 2022) on 6ix